Namrata Vijayvergia is an Oncology physician affiliated with Fox Chase Cancer Center. OpenAlex indexes 132 publications with 2,461 citations (h-index 20); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
- Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy
Sponsor: Fox Chase Cancer Center
- Regorafenib Plus 5-Fluorouracil/Leucovorin Beyond Progression in mCRC
Sponsor: Fox Chase Cancer Center
- A Study of Pembrolizumab in Patients With Neuroendocrine Tumors
Sponsor: Fox Chase Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
19 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year20253 payments
- E.R. Squibb & Sons, L.L.C.Program year20252 payments
- Exelixis Inc.Program year202515 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
2 NIH research awards on record, funded 2020–2025 per NIH RePORTER. The latest:
- Exploring the Neuroprotective Potential of CBD in Preventing Oxaliplatin-Induced Neuropathy: A Prospective Study
Research Inst of Fox Chase Can Ctr
FY2025$429,162R21CA292276 - Systematic study of variations in imaging techniques and response criteria for well differentiated pancreatic neuroendocrine tumors
Research Inst of Fox Chase Can Ctr
FY2021$92,150R03CA219722 - Systematic study of variations in imaging techniques and response criteria for well differentiated pancreatic neuroendocrine tumors
Research Inst of Fox Chase Can Ctr
FY2020$92,150R03CA219722
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Consensus Guideline for the Management of Colorectal Cancer with Peritoneal Metastases
Annals of Surgical Oncology
2025 - Consensus Guideline for the Management of Peritoneal Metastases from Neuroendocrine Neoplasms
Annals of Surgical Oncology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Elizabeth Plimack, MD
Fox Chase Cancer Center
Martin Edelman, MD
Fox Chase Cancer Center
Shazia Nakhoda, MD
Fox Chase Cancer Center
Hossein Borghaei, MD
Fox Chase Cancer Center
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”